IMPACT Study Physician at Institute of Human Virology, Nigeria

Responsibilities

• Will undergo and complete cancer prevention training on the job and will maintain their certification throughout the duration of the position.
• Gently communicate with vulnerable patients about the pathogenesis of human papillomavirus (HPV), the risk of developing anal cancer, and the options for prevention and treatment procedures.
• Assess patients for anal cancer by conducting anal swabbing, digital anal rectal examination, and high-resolution anoscopy (HRA)-directed biopsy sampling for histology diagnosis.
• Document cases in logbook on REDCap include notes about the procedure and impressions.
• Work with pathology and communicate histological findings, implications of a high-grade precancer (HSIL) diagnosis as well as discussing the treatment plan with the patient.
• Treat patients for high-grade precancerous lesions (HSIL) using hyfrecation/electrocautery for ablation. Prescribe medications as indicated.
• Evaluate treatment progress, assess health and well-being of the patient, and document findings.
• Refer patients for further care for any dysplasia that cannot be addressed at the clinic level and any suspected cases of cancer.
• Encourage participants to return for annual anal cancer screening.
• Engage with the study and implementation science teams to improve the development of the program.
• Participate in weekly and biweekly IMPACT Local and International meetings respectively.

Educational qualifications and experience

• Must possess a degree in Medical Sciences (MBBS or equivalent). Post graduate qualification/Master’s level training in Public Health or Epidemiology is an advantage.
• Must be registered with the Medical and Dental Council of Nigeria and possess a current medical practicing license.
• Having a fellowship in Surgery or O&G is an advantage.
• Previous experience in HIV-related, implementation science, or cancer research is an advantage.
• Good knowledge of current trends and normative guidance in HIV or cancer clinical care and service delivery amongst vulnerable population will be an advantage.